Cargando…

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

OBJECTIVES: Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect of inhaled COPD treatments on CVD outcomes and safety in patients with COPD and at heightened CVD risk. METHODS: The SUMMIT (Study to Understand Mortality and MorbidITy) wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brook, Robert D, Anderson, Julie A, Calverley, Peter MA, Celli, Bartolome R, Crim, Courtney, Denvir, Martin A, Magder, Sheldon, Martinez, Fernando J, Rajagopalan, Sanjay, Vestbo, Jørgen, Yates, Julie, Newby, David E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Heart 2017
Materias:	Pulmonary Vascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629944/ https://www.ncbi.nlm.nih.gov/pubmed/28416587 http://dx.doi.org/10.1136/heartjnl-2016-310897

Ejemplares similares

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019)

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
por: Adamson, Philip D., et al.
Publicado: (2018)

FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
por: Bikov, Andras, et al.
Publicado: (2020)

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
por: Vestbo, Jørgen, et al.
Publicado: (2019)

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
por: Byrd, James Brian, et al.
Publicado: (2018)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2022)

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review
por: Celli, Bartolome R., et al.
Publicado: (2021)

MASSIVE PULMONARY EMBOLISM TREATED WITH THROMBOLYSIS IN COVID-19: A CASE SERIES
por: Alarcon-Calderon, Amarilys, et al.
Publicado: (2020)

Performance of fractional exhaled nitric oxide in predicting response to inhaled corticosteroids in chronic cough: a meta-analysis
por: Ambrosino, Pasquale, et al.
Publicado: (2021)

A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease
por: Hardin, Megan, et al.
Publicado: (2015)

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021)

Inhaled corticosteroid dose is associated with Pseudomonas aeruginosa infection in severe COPD
por: Shafiek, Hanaa, et al.
Publicado: (2021)

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
por: Jones, Paul W, et al.
Publicado: (2011)

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
por: Jenkins, Christine R, et al.
Publicado: (2009)

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD
por: Kreindler, James L, et al.
Publicado: (2016)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial
por: Wise, Robert A, et al.
Publicado: (2020)

Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study
por: Heerfordt, Christian Kjer, et al.
Publicado: (2023)

Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease
por: Eklöf, Josefin, et al.
Publicado: (2022)

Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
por: Ghio, Stefano, et al.
Publicado: (2016)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Fukui, Shigefumi, et al.
Publicado: (2016)

Right heart function during simulated altitude in patients with pulmonary arterial hypertension
por: Seccombe, Leigh M, et al.
Publicado: (2017)

Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review
por: Varela, Daniel L, et al.
Publicado: (2018)

Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
por: Han, Yuchi, et al.
Publicado: (2018)

Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper
por: Abraham, Paul, et al.
Publicado: (2018)

Prognostic relevance of the right ventricular myo-mechanical index (RV-MMI) in patients with precapillary pulmonary hypertension
por: Greiner, Sebastian, et al.
Publicado: (2018)

Mechanisms of ECG signs in chronic obstructive pulmonary disease
por: Larssen, Marte Strømsnes, et al.
Publicado: (2017)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
por: Gerhardt, Felix, et al.
Publicado: (2017)

CENTRAL AND PERIPHERAL VENOUS THROMBOSIS IN NON-MECHANICALLY VENTILATED SURVIVORS OF COVID-19
por: Nauka, Peter, et al.
Publicado: (2020)

ACUTE PULMONARY EMBOLISM AND MYOCARDIAL INJURY IN COVID-19 PATIENT
por: Alfaki, Musaab, et al.
Publicado: (2020)

ANTICOAGULATION AND COVID-19: A META-ANALYSIS
por: Ho, Kam Sing, et al.
Publicado: (2020)

PULMONARY EMBOLISM AND RIGHT HEART STRAIN PATTERN IN COVID-19: AN INCIDENTAL FINDING OR A PERSISTENT PATTERN?
por: Roomi, Sohaib, et al.
Publicado: (2020)

PHLEGMASIA CERULEA DOLENS: AN ATYPICAL COVID-19 PRESENTATION
por: Akkari, Riad, et al.
Publicado: (2020)

COVID-19-ASSOCIATED COAGULOPATHY AS A PRESENTATION OF CORONAVIRUS DISEASE 2019: A PATIENT PRESENTS WITH A LARGE STROKE, PULMONARY EMBOLISM, AND DVT
por: Ramanathan, Rudra, et al.
Publicado: (2020)

Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase
por: DiNicolantonio, James J, et al.
Publicado: (2020)

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
por: Pagnesi, Matteo, et al.
Publicado: (2020)

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension
por: Chouvarine, Philippe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_snkn0aubcfg4clmqr33ppsbkak